Low carbohydrate diet and improved glycaemic control in a patient with type one diabetes

Mirjam Eiswirth¹, Ewan Clark² and Michael Diamond²
¹University of Edinburgh, Edinburgh, UK and ²University of Edinburgh Health Centre, Edinburgh, UK

Summary

We present the case of an adult female with type 1 diabetes, whose HbA1c was trending at 58 mmol/mol (7.5%) for the past 3 years. In August 2016, she reduced her total daily carbohydrate intake to 30–50 g and adjusted her other macronutrients to compensate for the calorific deficit. Her HbA1c fell to 34 mmol/mol (5.3%) by January 2017 and average daily blood glucose readings decreased significantly from 10.4 to 6.1 mmol/L. Moreover, she observed a marked reduction of average daily glucose variability. Notably, there were no significant episodes of hypo- or hyperglycaemia and her lipid profile remained static. Subjectively, she described an improvement in her quality of life and the dietary transition was extremely well tolerated. We discuss these findings in detail and the potential clinical benefits for patients with type 1 diabetes that can be gained by following a low carbohydrate diet.

Learning points:

• A low carbohydrate diet was found to substantially reduce HbA1c values and blood glucose (BG) variability, as well as causing a significant reduction in average daily glucose values in a patient with T1DM.
• Although further research is warranted, low carbohydrate diets in patients with T1DM have the potential to positively impact long-term morbidity and mortality through reduction of BG variability and average daily BG values.
• The diet was well tolerated and not associated with any adverse effects within this study.

Background

Type 1 diabetes mellitus (T1DM) is an autoimmune disease, resulting in the self-destruction of pancreatic islet beta cells. The eventual outcome is cessation of endogenous insulin production in response to rising blood glucose (BG) levels. It is associated with a significant pathological burden, and has been well established that poor glycaemic control correlates with increasing morbidity and mortality (1).

Glycosylated haemoglobin (HbA1c) is a marker of glycaemic control, representing an approximate average of BG levels over a three-month period. The non-diabetic population has a HbA1c of less than 42 mmol/mol (6.0%). However, in T1DM, target levels at or below 48 mmol/mol (6.5%) are generally considered desirable (2). Achieving good glycaemic control can be an arduous process for patients, as it requires careful and educated matching of carbohydrate intake with insulin. Physical activity, exogenous stress or hormonal change can significantly influence insulin requirement and BG homeostasis (3). Poor control is also often represented by erratic daily BG levels. This in turn is frequently associated with an elevated HbA1c, a hallmark of chronic hyperglycaemic
Insulin. More acutely, steep BG variations greatly increase the potentially mortal risks of severe hypoglycaemia and/or ketoacidosis.

Before the advent of exogenous insulin, the only medical treatment available was a strict adherence to a low carbohydrate diet. Today, insulin is most commonly injected as a long-acting basal regime combined with short-acting boluses for corrective doses. The extracorporeal subcutaneous insulin pump and the recent advent of glucose monitoring sensors (both flash and continuous) have facilitated a closer approximation of normal physiology in type 1 patients. Despite these advances, we are still struggling to achieve normal BG control in this population. Moreover, there is limited evidence examining the impact of a very low carbohydrate diet on overall glycaemic control (HbA1c, average BG and variability) in patients with T1DM.

**Case presentation**

The patient presented here is a female in her twenties who was diagnosed with T1DM at the age of five years. She commenced insulin pump therapy at the age of 13 years and had stable control of her diabetes over the past decade. The patient had previously attended several courses similar to DAFNE (dose adjustment for normal eating). HbA1c readings from 2013 until mid-2016 ranged from 54 to 62 mmol/mol (7.1–7.8%), and she had no end-organ diabetic complications. Her insulin pump was a Medtronic 640g and BGs were monitored using a Freestyle Libre metre. When BG readings were higher than 10 mmol/L or lower than 3.5 mmol/L, she would routinely cross-check with a Bayer Contour Next monitor. HbA1c values (mmol/mol) were obtained from routine clinical monitoring.

For comparative reference, fasting BG levels in non-diabetic individuals are less than 7 mmol/L. There was a sharp decline in the HbA1c well below the diagnostic cut-off for diabetes (42 mmol/mol or 6.0%). Notably, the patient's total daily requirements for insulin were reduced from 50 to 30 units. In summary, these changes were facilitated by a reduction in carbohydrate intake to an amount of 30–50 g daily.

**Figure 1** plots the average daily BG values, expressed as a percentage of daily caloric intake against time. There was a reduction of both inter-daily variability and average daily BG values. Prior to the dietary modification, the patient's BGs were trending at 10.4 mmol/L on a daily basis. However, after the intervention 6 months later, this had improved to a daily average of 6.1 mmol/L (Fig. 2). For comparative reference, fasting BG levels in non-diabetic individuals are less than 7 mmol/L. There was also a markedly reduced daily BG variability between the control and December values (27%). Figure 3 represents the patient’s HbA1c values over a 3-year period, showing a sharp decline in the HbA1c well below the diagnostic cut-off for diabetes (42 mmol/mol or 6.0%). Notably, the patient's total daily requirements for insulin were also reduced from 50 to 30 units. In summary, these data collectively demonstrate that not only was there a transition in the average BGs to a normal range, but the net variability was greatly reduced and HbA1c was normalised to a non-diabetic level.

It is important to note that when the described dietary change was effected, the patient did not experience any
significant episodes of hypoglycaemia. Additionally, her hyperglycaemic events were infrequent, less marked and of shorter duration than those she recorded previously. Interestingly, it also emerged that the patient found she had to make insulin dose adjustments for high protein/fat meals, as they consistently caused a greater postprandial rise in BG than would be expected from the calculated carbohydrate load alone. No episodes of diabetic ketoacidosis were experienced by the patient. Overall, her random ketone measurements were reported in the range of 0.3 – 0.6 mmol/L. The patient did report two episodes of a mild to moderate ketosis. On review, these were likely attributable to a miscalculation or a basal morning dose (ketones of 1.5 mmol/L) and a prolonged exercise bout of three hours (ketones of 2.2 mmol/L). Her other biochemical and haematological values remained static, with no adverse changes to her lipid profile (TC 4.0, LDL 2.1), and she described a marked improvement in her quality of life (see ‘Patient perspective’).

Discussion

The findings of this study clearly demonstrate that the impact of dietary manipulation on glycaemic control cannot be understated. The near normalisation of glycaemic control in this patient is likely multifactorial, and we propose several mechanisms underlying this. In general, a lower carbohydrate intake will inevitably lead to a proportionally smaller rise in BG. A smaller titration of insulin is consequently required, with a lower risk of over-correcting and in turn a reduction in overall glycaemic variability. Furthermore, with lower carbohydrate intake, muscular and liver stores of glycogen are less likely to be saturated. Thus, the maintenance of glucose homeostasis through active glycogenesis may contribute an important additional buffer to glycaemic control. Evidence from previous studies support this postulation, demonstrating that a glycogen-deplete state facilitates a more rapid uptake of circulating BG into muscular stores (4).
We acknowledge the limitation of this case study, primarily as it is confined to the observational data from one patient. However, previous research corroborates our findings. Krebs et al. (5) examined the effects of a low carbohydrate diet in patients with T1DM over 12 weeks. Dietary intake was restricted to an average 100 g per day and subjects noted an average decrease in HbA1c from 63 to 55 mmol/mol (7.9–7.2%). In 2006, Nielsen demonstrated that a daily intake of 70–90 g of carbohydrate significantly reduced hypoglycaemic events and lowered HbA1c from 58.5 to 46.4 mmol/mol (7.5–6.4%) after 3 months (6). Although not looking at absolute reduction in carbohydrate intake, a Cochrane review in 2009 (7) scrutinised 11 randomised control trials looking at the impact of low glycaemic index diets in diabetic management. The collective findings were lower average HbA1c values and a reduced frequency of hypoglycaemic and hyperglycaemic events. Finally, our study also demonstrated a clear reduction in daily BG variability, a measure which has been proposed to play a key role in the pathology of end-organ damage in diabetes (8). Although the referenced evidence supports our findings, our study is the first to observe a collective normalisation of glycaemic control (average BM, variability and HbA1c) with a very low carbohydrate diet.

We would caution that any such intervention be undertaken in a clinically supervised manner. Biochemically, a reduction in carbohydrate intake and subsequent down titration of insulin, increases the use of ketone bodies as an energy source. In patients with type 1 diabetes, this can potentiate the risks for diabetic ketoacidosis. In this case, flash glucose monitoring facilitated a safer environment in which to observe regular changes in daily BGs. Furthermore, the pump allowed careful titration of insulin according to dietary intake as well as baseline circadian variation. A potential obstacle to applying our findings to clinical practice is that a strict low carbohydrate diet may have problems of adherence; a fact to which previous researchers have alluded (6, 7). However, with all lifestyle change it may be that gradual dietary modification, ideally supported by a dietician, could facilitate an easier and sustained transition.

An interesting observation of this study was the patient had to make additional adjustments in her insulin dose for very high protein/fat content meals as they consistently caused a greater postprandial rise in BG than would have been expected from the calculated carbohydrate load alone. A recent systematic review of 14 clinical studies examined the impact of fat and protein on postprandial BG readings and repeatedly found that meals high in protein/fat required higher boluses of insulin than the expected carbohydrate load (9). Underpinning this observation, we know that certain amino acids can be converted into glucose (gluconeogenesis), and dietary fat slows the absorption of dietary glucose causing a delayed postprandial rise. The complex biochemistry behind this and its net impact on insulin dosing is the subject of much ongoing research and debate (10).

In summary, we present here compelling evidence that a low carbohydrate diet has a positive and sustained impact on glycaemic control in a patient with type 1 diabetes. It normalised large fluctuations in daily BG readings and lead to HbA1c values in the non-diabetic range. When extrapolating the data in this report, we would stress the need for personalised nutrition recommendations. Inherent metabolic differences exist between individuals and their response to dietary modification, namely a low carbohydrate high fat/protein may be varied. Therefore, a guided approach with close dietary supervision would be recommended for future research. Further, larger scale studies are needed to establish if these findings can be extrapolated across a more diverse subsection of this population and may in principle be applicable to management of insulin-dependent patients with type 2 diabetes. Moreover, extended follow-up of this patient group should allow an accurate assessment of impact on chronic micro- and macro-vascular morbidity, as well as long-term adherence to the diet.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Patient consent
The patient has given written informed consented for the publication of the details contained within this document.

Patient's perspective
The switch from 150 to 200 g of carbohydrates a day to a low carbohydrate diet has been liberating for me. With much more stable blood sugars, I have stopped suffering from the side effects of strong fluctuations and extreme blood sugar levels: I have fewer headaches, sleep better and am thus more well rested, have more stable energy levels throughout the day and feel satiated for longer (often with less food). The dietary adjustment also allows me to exercise more spontaneously with less of an impact on

http://www.edmcasereports.com
my BG levels. Having fewer and smaller glycaemic excursions also means that I spend a lot less mental and emotional energy on my diabetes management and am more relaxed and less anxious and frustrated than before.

Author contribution statement
Mirjam Eiswirth: Data analysis and graph construction written contribution to body of text. Ewan Clark: Written contribution to body of text and editing. Michael Diamond: Data analysis, graph construction, written contribution to body of text and editing.

References
7 Thomas D & Elliott EJ. Low glycaemic index, or low glycaemic load, diets for diabetes mellitus. Cochrane Database of Systematic Reviews 2009. (https://doi.org/10.1002/14651858.CD006296.pub2)

Received in final form 14 February 2018
Accepted 20 February 2018